The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predicting response to platinum chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) using a genomic signature for “BRCAness”: A phase II clinical trial of satraplatin in men with mCRPC who have progressed on docetaxel.
S. M. Seng
No relevant relationships to disclose
M. D. Galsky
Consultant or Advisory Role - Bristol-Myers Squibb; Foundation Medicine; GlaxoSmithKline; Pfizer
Research Funding - Celgene
C. Tsao
No relevant relationships to disclose
J. Li
No relevant relationships to disclose
P. G. Febbo
No relevant relationships to disclose
W. K. Oh
No relevant relationships to disclose